Dosage ; Dosages should be increased gradually.
Starting: 0.375mg/day in 3 divided doses.
It should not be increased more frequently than every 5 -7 day.
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Pexola | Boehringer Ingelheim International | Pharma Specialities Ltd. | 0.125mg | 100 | Tablet | per tablet | KES 2,600 |
| Pexola | Boehringer Ingelheim International | Pharma Specialities Ltd. | 0.25mg | 100 | Tablet | per tablet | KES 4,903 |
| Pexola | Boehringer Ingelheim International | Pharma Specialities Ltd. | 1mg | 100 | Tablet | per tablet | KES 10,455 |
| Pramipex | Sunlight International Trading (Africa) Co., Ltd | Harley's Limited | 0.25mg | 30 | Tablet | per tablet | KES 1,440.00 |
| Pramipex | Sunlight International Trading (Africa) Co., Ltd | Harley's Limited | 0.5mg | 30 | Tablet | per tablet | KES 2,250.00 |
| Pramipex | Sunlight International Trading (Africa) Co., Ltd | Harley's Limited | 1mg | 30 | Tablet | per tablet | KES 2,820.00 |
|
Pramipexole More Info |
|
|---|---|
| Mode Of Action | Pramipexole is a selective non-ergot dopamine agonist |
| Drug Indication | Idiopathic Parkinson's disease (as monotherapy without levodopa) or in combination with levodopa, moderate-to-severe primary restless legs syndrome. |
| Precautions | It causes drowsiness |
| Contra-Indications | Hypersensitivity to the active substance or to any of the excipients. |
| Side Effects | Dyskinesia, hallucinations, somnolence, insomnia, hallucinations, dry mouth, constipation, dizziness, orthostatic hypotension. |
| Dosage | Dosages should be increased gradually. Starting: 0.375mg/day in 3 divided doses. It should not be increased more frequently than every 5 -7 day. |
| Drug Category | DRUGS ACTING ON CNS |
| Drug Sub-Category | Rigidity and tremor controllers
Use Immediate release: Treatment of the signs and symptoms of idiopathic Parkinson's disease; treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) Extended release: Treatment of the signs and symptoms of idiopathic Parkinson’s disease Use - Unlabeled/Investigational Treatment of depression; treatment of fibromyalgia Dosing: Adult Parkinson's disease: Oral: Immediate release formulation: Initial: 0.375 mg/day given in 3 divided doses; increase gradually every 5-7 days; range: 1.5-4.5 mg/day. Extended release formulation (Mirapex® ER™): Initial: 0.375 mg once daily; increase gradually to 0.75 mg once daily. If necessary, may increase by 0.75 mg/dose not more frequently than every 5-7 days; maximum recommended dose 4.5 mg/day Note: Converting from immediate release to extended release: May initiate extended release preparation the morning after the last immediate release evening tablet is taken. The total daily dose should remain the same. Restless legs syndrome: Oral: Initial: 0.125 mg once daily 2-3 hours before bedtime. Dose may be doubled every 4-7 days up to 0.5 mg/day. Maximum dose: 0.5 mg/day (manufacturer’s recommendation). Note: Most patients require <0.5 mg/day, but higher doses have been used (2 mg/day). If augmentation occurs, dose earlier in the day. Depression (unlabeled use): Initial: 0.25-0.375 mg/day given in 2-3 divided doses with a gradual titration; mean dose: 1.6-1.7 mg/day (Aiken, 2007; Goldberg, 2004) Fibromyalgia (unlabeled use): Initial: 0.25 mg once daily at bedtime; may be increased weekly by 0.25 mg/day increments up to 4.5 mg/day (Holman, 2005) Dosing: Geriatric Refer to adult dosing. Dosing: Renal Impairment Use caution; renally-eliminated Parkinson's disease: Immediate release formulation: Clcr 35-59 mL/minute: Initial: 0.125 mg twice daily (maximum dose: 1.5 mg twice daily) Clcr 15-34 mL/minute: Initial: 0.125 mg once daily (maximum dose: 1.5 mg once daily) Clcr <15 mL/minute: Not adequately studied Hemodialysis: Not adequately studied; a negligible amount of pramipexole is removed by dialysis Parkinson's disease: Extended release formulation: Clcr >50 mL/minute: Dosing adjustment not necessary Clcr 30-50 mL/minute: Initial: 0.375 mg every other day; may increase to 0.375 mg once daily no sooner than 1 week after initiation. If necessary, may increase by 0.375 mg/dose not more frequently than every 7 days; maximum recommended dose: 2.25 mg/day Clcr <30 mL/minute: Not recommended Hemodialysis: Not recommended; a negligible amount of pramipexole is removed by dialysis Restless legs syndrome: Immediate release formulation: Clcr 20-60 mL/minute: Duration between titration should be increased to 14 days Clcr <20 mL/minute: Not adequately studied |